Rosiglitazone regulates astrocyte polarization and neuroinflammation in a PPAR-γ dependent manner after experimental traumatic brain injury

• Published in: Brain research bulletin Vol. 209; p. 110918
• Main Authors: Ren, Xu, Li, Yun-Fei, Pei, Tian-Wei, Wang, Hao-Sheng, Wang, Yu-Hai, Chen, Tao
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01-04-2024; Elsevier
• Subjects: Astrocyte polarization; Neuroinflammation; PPAR-γ pathway; Rosiglitazone; Traumatic brain injury; Rosiglitazone; Neuroinflammation; Traumatic brain injury; Astrocyte polarization; PPAR-γ pathway
• ISSN: 0361-9230; 1873-2747
• DOI: 10.1016/j.brainresbull.2024.110918

Traumatic brain injury (TBI) is a leading cause of high mortality and disability worldwide. Overactivation of astrocytes and overexpression of inflammatory responses in the injured brain are characteristic pathological features of TBI. Rosiglitazone (ROS) is a peroxisome proliferator-activated receptor-γ (PPAR-γ) agonist known for its anti-inflammatory activity. However, the relationship between the inflammatory response involved in ROS treatment and astrocyte A1 polarization remains unclear.
This study aimed to investigate whether ROS treatment improves dysfunction and astrocyte A1 polarization induced after TBI and to elucidate the underlying mechanisms of these functions.
SD rats were randomly divided into sham operation group, TBI group, TBI+ROS group, and TBI+ PPAR-γ antagonist group (GW9662 + TBI). The rat TBI injury model was prepared by the CCI method; brain water content test and wire grip test scores suggested the prognosis; FJB staining showed the changes of ROS on the morphology and number of neurons in the peripheral area of cortical injury; ELISA, immunofluorescence staining, and western blotting analysis revealed the effects of ROS on inflammatory response and astrocyte activation with the degree of A1 polarization after TBI.
Brain water content, inflammatory factor expression, and astrocyte activation in the TBI group were higher than those in the sham-operated group (P < 0.05); compared with the TBI group, the expression of the above indexes in the ROS group was significantly lower (P < 0.05). Compared with the TBI group, PPAR-γ content was significantly higher and C3 content was considerably lower in the ROS group (P < 0.05); compared with the TBI group, PPAR-γ content was significantly lower and C3 content was substantially higher in the inhibitor group (P < 0.05).
ROS can exert neuroprotective effects by inhibiting astrocyte A1 polarization through the PPAR-γ pathway based on the reduction of inflammatory factors and astrocyte activation in the brain after TBI.
•Rosiglitazone could promote the recovery of neurological function after TBI in rats.•Rosiglitazone inhibited neuroinflammation and proliferative activation of astrocytes after TBI in rats.•On this basis, Rosiglitazone inhibited the A1 polarization of astrocytes.•Rosiglitazone inhibited the A1 polarization through the PPAR-γ pathway.